Skip to main content
Clinical Trials/NCT05085080
NCT05085080
Withdrawn
Not Applicable

Chinese Neonatal Extracorporeal Life Support Registry (Chi-NELS)

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Extracorporeal Life Support
Sponsor
Children's Hospital of Fudan University
Primary Endpoint
Overall mortality
Status
Withdrawn
Last Updated
2 years ago

Overview

Brief Summary

Extracorporeal life support (ECLS), also known as extracorporeal membrane oxygenation (ECMO), is an extracorporeal technique which provides respiratory and cardiac support to patients with respiratory and/or heart failure. Neonates account for a significant proportion of patients requiring ECLS support. While with unique pathophysiology among newborn infants, neonatal ECLS treatment faces different challenges (such as specific indications, anticoagulation, hemodynamic management, high incidences of complications, ect.) from those of elder children or adults. Though neonatal ECMO has been used in developed countries since 1970s, the introduction of neonatal ECMO in China was not reported until 2010s. While on the other hand, there has been a rapid increase of neonatal ECLS cases and centers in China in the past decade with a huge variation of numbers of cases and quality among different centers. Therefore, there is an urgent need to monitor the use and quality of neonatal ECLS in China. The goal of the Chinese Neonatal Extracorporeal Life Support Registry (Chi-NELS) is to maintain a registry of use of ECLS in active neonatal ECLS centers across China, to support quality improvement of neonatal ELCS, clinical research and regulatory agencies.

Detailed Description

This study aims to establish a neonatal ECLS network of all active ECLS centers in China to facilitate standardization of care and collaborative research. On the basis of the network, this prospective comprehensive registry will enroll all neonates who receive ECLS support in participating centers. The indications, managements, complications and outcomes of neonatal ECLS in China will be described in detail, to monitor the development of neonatal ECLS in China, to identify targets for quality improvement, to assist in reducing mortality and morbidity of neonates requiring ECLS support, and to facilitate innovative clinical researches.

Registry
clinicaltrials.gov
Start Date
January 1, 2024
End Date
December 31, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ≤28 days of life
  • receive ECLS support

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Overall mortality

Time Frame: From admission to discharge or death, an average of 3 months

Mortality during NICU

Secondary Outcomes

  • Incidence of renal failure(From admission to discharge or dealth, an average of 3 months)
  • Incidence of CPR required(From admission to discharge or dealth, an average of 3 months)
  • Incidence of pulmonary hemorrhage(From admission to discharge or dealth, an average of 3 months)
  • Rate of successful weaning from ECLS(From admission to discharge or dealth, an average of 3 months)
  • Incidence of hemorrhage(From admission to discharge or dealth, an average of 3 months)
  • Incidence of cardiac arrhythmia(From admission to discharge or dealth, an average of 3 months)
  • Length of hospital stay(From admission to discharge or dealth, an average of 3 months)
  • Length of mechanical ventilation(From admission to discharge or dealth, an average of 3 months)
  • Incidence of mechanical complications(During ECLS, an average of 3 months)
  • Incidence of brain death(From admission to discharge or dealth, an average of 3 months)
  • Incidence of seizure(From admission to discharge or dealth, an average of 3 months)
  • Incidence of CNS infarction(From admission to discharge or dealth, an average of 3 months)
  • Incidence of pneumothorax(From admission to discharge or dealth, an average of 3 months)
  • Incidence of infection(From admission to discharge or dealth, an average of 3 months)
  • Incidence of limb ischemia(From admission to discharge or dealth, an average of 3 months)
  • Incidence of diffuse ischemia of central nervous system (CNS)(From admission to discharge or dealth, an average of 3 months)
  • Incidence of intraventricular hemorrhage(From admission to discharge or dealth, an average of 3 months)
  • Incidence of hemolysis(From admission to discharge or dealth, an average of 3 months)
  • Cost of hospital stay(From admission to discharge or dealth, an average of 3 months)

Similar Trials